Skip to main content

Table 2 Clinicopathological characteristics in association with ROS1, ALK, PD-1, and PD-L1 proteins expression

From: The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt

   ROS1 ALK PD-1 PD-L1
No -ve +ve -ve +ve -ve +ve -ve +ve
Age
 < 55 32 27 (84.4) 5 (15.6) 14 (43.75) 18 (56.25) 4 (12.5) 28 (87.5) 4 (12.5) 28 (87.5)
 ≥ 55 38 30 (78.9) 8 (21.1) 18 (47.4) 20 (52.6) 7 (18.4) 31 (81.6) 5 (13.2) 33 (86.8)
ap-value   0.76 0.81 0.53 1.00
Gender
 Female 19 16 (84.2) 3 (15.8) 9 (47.4) 10 (52.6) 5 (26.3) 14 (73.7) 4 (21.1) 15 (78.9)
 Male 51 41 (80.4) 10 (19.6) 23 (45.1) 28 (54.9) 6 (11.8) 45 (88.2) 5 (9.8) 46 (90.2)
ap-value   1.00 1.00 0.15 0.24
Smoking status
 Never-smoker 27 22 (81.5) 5 (18.5) 13 (48.1) 14 (51.9) 5 (18.5) 22 (81.5) 3 (11.1) 24 (88.9)
 Current/ex-smoker 41 35 (81.4) 8 (18.6) 19 (44.2) 24 (55.8) 6 (13.95) 37 (86.05) 6 (13.95) 37 (86.05)
ap-value   1.00 0.81 0.74 1.00
Grade
 1–2 51 41 (80.4) 10 (19.6) 24 (47.1) 27 (52.9) 7 (13.7) 44 (86.3) 8 (15.7) 43 (84.3)
 3 19 16 (84.2) 3 (15.8) 8 (42.1) 11 (57.9) 4 (21.1) 15 (78.9) 1 (5.3) 18 (94.7)
ap-value   1.00 0.79 0.47 0.43
Stage
 I 12 8 (66.7) 4 (33.3) 10 (83.3) 2 (16.7) 3 (25.0) 9 (75.0) 1 (8.3) 11 (91.7)
 II 15 13 (86.7) 2 (13.3) 9 (60.0) 6 (40.0) 3 (20.0) 12 (80.0) 3 (20.0) 12 (80.0)
 III 12 11 (91.7) 1 (8.3) 6 (50.0) 6 (50.0) 2 (16.7) 10 (83.3) 1 (8.3) 11 (91.7)
 IV 31 25 (80.6) 6 (19.4) 7 (22.6) 24 (77.4) 3 (9.7) 28 (90.3) 4 (12.9) 27 (87.1)
bp-value   0.42 0.002** 0.60 0.77
Tumor size (cm
 < 4 25 21 (84.0) 4 (16.0) 14 (56.0) 11 (44.0) 2 (8.0) 23 (92.0) 4 (16.0) 21 (84.0)
 ≥ 4 45 36 (80.0) 9 (20.0) 18 (40.0) 27 (60.0) 9 (20.0) 36 (80.0) 5 (11.1) 40 (88.9)
ap-value   0.76 0.22 0.31 71.2
Laterality
 Left 36 27 (75.0) 9 (25.0) 12 (33.3) 24 (66.7) 3 (8.3) 33 (91.7) 2 (5.6) 34 (94.4)
 Right 34 30 (88.2) 4 (11.8) 20 (58.8) 14 (41.2) 8 (23.5) 26 (76.5) 7 (20.6) 27 (79.4)
ap-value   0.22 0.04* 0.10 0.08
LN metastasis
 No 34 28 (82.4) 6 (17.6) 17 (50.0) 17 (50.0) 5 (14.7) 29 (85.3) 5 (14.7) 29 (85.3)
 Yes 36 29 (80.6) 7 (19.4) 15 (41.7) 21 (58.3) 6 (16.7) 30 (83.3) 4 (11.1) 32 (88.9)
ap-value   1.0 0.63 1.0 0.73
EGFR mutation
 Wild type 40 32 (80.0) 8 (20.0) 19 (47.5) 21 (52.5) 8 (20.0) 32 (80.0) 6 (15.0) 34 (85.0)
 Mutant 21 17 (80.95) 4 (19.05) 7 (33.3) 14 (66.7) 2 (9.5) 19 (90.5) 2 (9.5) 19 (90.5)
 Unknown 9 8 (88.9) 1 (11.1) 6 (66.7) 3 (33.3) 1 (11.1) 8 (88.9) 1 (11.1) 8 (88.9)
bp-value   0.82 0.23 0.52 0.82
  1. LN lymph node, EGFR epidermal growth factor receptor, ROS1 c-ros oncogene1, ALK anaplastic lymphoma kinase, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1
  2. **Significant at p < 0.01
  3. aFisher exact test was used
  4. bChi-square test was used